Johnson & Johnson : Announces Fireside Chat Webcast on Janssen’s Eye Disease Portfolio

News Release

Media Contact:

Jennifer Silvent

Mobile: [phone]

[e-mail]

Investor Contacts:

Chris DelOrefice

Mobile: [phone]

Jennifer McIntyre

Office: [phone]

Johnson & Johnson Announces Fireside Chat Webcast on

Janssen's Eye Disease Portfolio

NEW BRUNSWICK, NJ, December 3, 2020 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new pre-recorded fireside chat webcast focused on the company's eye disease portfolio. Hosted by Cowen, the webcast is intended for investors and other interested parties, and can be accessed at the Johnson & Johnson

website www.investor.jnj.comby clicking on "Webcasts/Presentations."

The webcast features James F. List, M.D., Ph.D., Global Therapeutic Area Head, Cardiovascular & Metabolism, Janssen Research & Development, LLC, discussing recently-

presented data from the company's lead gene therapy asset AAV-RPGR in development with

MeiraGTx for the treatment of inherited retinal disease X-linked retinitis pigmentosa. Dr. List

also discusses how Janssen's eye disease portfolio complements Johnson & Johnson's long-

standing heritage in vision care.

The webcast duration is approximately 20 minutes and will be available through the end of December 2020.

Cautionary Note on Forward-Looking Statements

The webcast may contain "forward-looking statements" regarding, among other things, future operating and financial performance, product development, market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize,

Page 1 of 2

actual results could vary materially from the expectations and projections of Johnson & Johnson. A list of risks, uncertainties and other factors can be found in Johnson & Johnson's filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 29, 2019 and our most recently filed Quarterly Report on Form 10-Q. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson assumes no obligations to update any forward-looking statement as a result of new information or future events or developments.

###

Page 2 of 2